Molecular Methods for Detection of Minimal Residual Disease Following Transplantation in Lymphoid and Plasma Cell Disorders-Reference-Cited by-同舟云学术

Molecular Methods for Detection of Minimal Residual Disease Following Transplantation in Lymphoid and Plasma Cell Disorders

Published:2013-12-27 Issue: Volume: Page:209-237
ISSN:1064-3745
Container-title:Methods in Molecular Biology
language:
Short-container-title:

Author:

Corradini Paolo,Carniti Cristiana

Publisher

Springer New York

Link

http://link.springer.com/content/pdf/10.1007/978-1-4614-9437-9_12

Reference34 articles.

1. Farina L, Carniti C, Dodero A et al (2009) Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 94:654–662

2. Corradini P, Ladetto M, Zallio F et al (2004) Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 22:1460–1468

3. Corradini P, Tarella C, Olivieri A et al (2002) Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99:75–82

4. Corradini P, Cavo M, Lokhorst H et al (2003) Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 102:1927–1929

5. Román J, Alvarez MA, Torrea A (2000) Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Haematologica 85:1072–1082

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features;Biology of Blood and Marrow Transplantation;2016-11

2. Multiple Myeloma Minimal Residual Disease;Plasma Cell Dyscrasias;2016

3. Continuous Reduced Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Institution’s Three Decade Experience;Biology of Blood and Marrow Transplantation;2014-08